Inari Medical, Inc. ((NARI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The PEERLESS II Study, officially titled ‘PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism,’ is a prospective, multicenter, randomized controlled trial. It aims to compare the effectiveness of the FlowTriever System plus anticoagulation against anticoagulation alone in treating intermediate-risk acute pulmonary embolism (PE). This study is significant as it could potentially redefine treatment protocols for PE, offering insights into more effective management strategies.
The interventions being tested include the FlowTriever System, a mechanical thrombectomy device designed to remove blood clots, and standard anticoagulation medications such as Heparin Sodium and Rivaroxaban, which help prevent blood clotting.
The study follows an interventional design with randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose of the study is treatment-focused, aiming to determine the most effective approach for managing intermediate-risk acute PE.
The study began on November 17, 2023, with its primary completion and estimated overall completion dates yet to be determined. The last update was submitted on July 8, 2025. These dates are crucial as they mark the progress and timeline for potential results that could influence clinical practices.
The outcome of this study could significantly impact Inari Medical’s stock performance, as positive results may enhance the company’s market position in the medical device industry. Investors should monitor updates closely, as successful trials could also affect competitor dynamics in the PE treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.